Part of the debate – in the House of Lords am 4:41 pm ar 22 Gorffennaf 2024.
My Lords, I join other noble Lords in congratulating the noble Lord, Lord Vallance of Balham, on his excellent maiden speech and the very thoughtful way in which he has introduced today’s debate. In so doing, I remind noble Lords of my own interest—in particular, that I am chairman of King’s Health Partners, UK Biobank and the Office for Strategic Coordination of Health Research, as well as serving as chancellor of the University of Lincoln.
In opening this debate, the noble Lord identified the importance of science and innovation to so many elements of His Majesty’s Government’s current agenda. The mission agenda ensures that the impact of economic growth benefits citizens as quickly as possible. Among the different domains and disciplines of science, life sciences play a particularly important role in providing the opportunity not only for substantial wealth creation in the economy but for substantial health gain, as the product of life sciences innovation is applied to practice in the NHS and, most importantly, to preventing ill health.
The Minister identified a number of potential hurdles that need to be overcome to ensure that the life sciences industry in our country and the broader ecosystem can progress at a rate that can make a meaningful impact. He mentioned the need for the development of new infrastructure and to secure growth funding to allow spin-outs and small-stage companies to develop at the pace that will provide maximal opportunity.
There are four other important areas that require very careful and immediate attention from His Majesty’s Government if the true potential of life sciences in our country is to be realised. I would be grateful if the Minister who will close the debate—my noble friend Lord Livermore—might be able to reflect on what approach His Majesty’s Government are going to take.
First, there is the question of free movement of scientists into our country and, in particular, the visa regime that is currently employed and the ease with which it can be used to encourage brilliant scientists to come and settle here and contribute not only to work in our universities but in the broader life sciences sector.
Secondly, there is the question of securing the research science base in our universities. Regrettably, that has been eroded over time. QR funding and full economic cost recovery have not been achieved appropriately for many years, and now charities and other funders of research find it very difficult to ensure that brilliant research programmes can be applied. We all recognise that overseas student income is a fundamental part of the university business model, to underwrite the opportunity for the science base in our universities. There is uncertainty about the future of large numbers of overseas students coming to our country, and His Majesty’s Government will need to address urgently the approach to securing the research base in our universities, which is critical not only to creating the talent that will service the life sciences sector but to securing the intellectual base of many of our research-led universities.
The third area is ensuring that the NHS, under substantial pressure to ensure clinical delivery, does not miss the opportunity to play its vital role in life sciences research and development. We must have a strategy to develop clinical academics, so that this part of the overall workforce continues to be nurtured and we have sufficient clinical academics able to serve and provide the opportunity for clinical translation and the rapid application of innovation to improve human health and outcomes in our National Health Service. This is particularly important since ill health is now such a drag on the economy and therefore, in addition to many other measures, innovation delivered through academic medicine will be vital to overcome that problem.
The final area that needs to be urgently addressed, as the Minister—my noble friend Lord Vallance—identified himself in his maiden speech, is the question of data. It is one thing to talk about or focus on the technological advances that will provide federated platforms for the use of the substantial datasets that we have available in our country, quite unique in the world; it is quite another to secure the social licence that will ensure that there is broad public support for the use of those data to drive forward the life sciences research agenda. Will the Minister comment on the approach that His Majesty’s Government propose to take to establish that social licence?